Oct 14, 2009
By:
George Koroneos, Online Content & News Editor
Sandoz Shire Pharmaceuticals announced that it would allow Sandoz to market a generic version of its blockbuster ADHD med Adderall XR if it can clear FDA. But that's a big if.
|
Oct 14, 2009
By:
George Koroneos, Online Content & News Editor
GSK is being ordered to pay $2.5 million in restitution to a Pennsylvania family. The firm was accused of not doing enough to warn consumers that taking the antidepressant Paxil, while pregnant, could lead to birth defects.
|
Oct 8, 2009
By:
George Koroneos, Online Content & News Editor
Sure, industry growth is at "historically low levels," but at least pharma is still growing. The industry's market value should surpass $825 billion in 2010, and forecasted growth was bumped up one percentage point from original estimates.
|
Oct 7, 2009
By:
George Koroneos, Online Content & News Editor
Pulling off an incredibly fast turnaround, the pharma industry has released a vaccine for the H1N1 virus, bolstering its bottom line with a second flu vaccine and potentially helping millions of people. So why is there such an uproar over whether it's safe?
|
Sep 30, 2009
By:
George Koroneos, Online Content & News Editor
Illegal online pharmacies are on the rise, brandjacking dozens of big name pharmaceuticals and netting almost $11 billion in sales this year alone. With consumers on the hunt for affordable meds, the trend is only going to get worse.
|
Sep 30, 2009
By:
George Koroneos, Online Content & News Editor
Just months on the job and GSK’s new president of North American Pharmaceuticals Deirdre Connelly is already making her presence known. Her latest move—spearheading an initiative that will boost funding to autonomous CME programs and cut commercial medical education programs. Pharm Exec spoke with Connelly to find out more.
|
Sep 16, 2009
By:
George Koroneos, Online Content & News Editor
Elan was forced to trim $100 million off its billion-dollar deal with J&J due to a 50/50 agreement with Biogen Idec involving co-ownership of MS drug Tysabri. Now J&J is out a major drug, Elan is out a good chunk of cash, and Biogen Idec is pondering its next move.
|
Sep 14, 2009
By:
George Koroneos, Online Content & News Editor
Eli Lilly announced this morning that it would eliminate approximately 5,500 positions as part of a massive reorganization strategy that's expected to net the firm reduce $1 billion in costs by 2011.
|
Sep 9, 2009
By:
George Koroneos, Online Content & News Editor
Some shareholders think they were shafted in the multi-billion dollar deal between Sepracor and Dainippon Sumitomo Pharma. They're so miffed, in fact, that they've filed a lawsuit stating that the amount offered undervalues the company and its shares.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
